Navigation Links
Animal insulin product to be discontinued by drug major Eli Lilly

The Chairman and Managing Director of Eli Lilly and Co., India, disclosed on January 3rd, during the announcement of a price cut in the company's human insulin product 'Huminsulin', that its animal insulin product 'Iletin' will be phased out from the market by the end of this year. He added that the company// resorted to this move due to the growing use of human insulin products and the phasing out of animal insulin products by other drug companies throughout the world.

A 10 ml vial of humininsulin, which was earlier available at a cost of Rs. 218, will now be available at Rs. 145 (a 33.5 per cent reduction from the former price),pegging it to prevailing prices of animal-derived insulin. This cut in price is as result of the drug now being manufactured at the Sun Pharmaceuticals plant at Halol, Gujarat.

Mr. Gulati also added that a new product, "inhaled insulin", is being developed by its parent company in the United States along with an Indian scientist and that the company is awaiting the governments approval for the phase II and III trials for this inhaled version. However, he added that the drug will cost more due to higher dose requirements compared to the injectible form and will be available only five years down the line.


'"/>




Page: 1

Related medicine news :

1. Animal Fat Enhances Risk Of Stomach
2. Cancer hazard Found With Animal-Based Nutrients
3. Animal Fat increases risk Of stomach cancer
4. Animals Can give us a second chance at life
5. Animals can give us a second chance at life
6. SARS vaccine shows promise in Animal Testing
7. Kidneys Can Be Transplanted From Animals Such As Pigs In Future
8. Broccoli Found to Block Cancer Progression In Both Animal and Human Studies
9. Animal Cruelty free Test Kit
10. Increase in the Number of Cases of Animal Diseases in New South Wales.
11. Herbal Medicines with Animal, Human Body Parts! - Swami Ramdev Accused

Post Your Comments:
(Date:11/24/2009)...to a significantly higher risk of strokes and card... in the British Medical Journal . , The researc...nization,s Collaborating Centre for Nutrition, bas...pital in Coventry, UK, and the European Society of...sed at the Department of Clinical and Experimental...
(Date:11/24/2009)...sity School of Medicine (BUSM) and the Boston Univ...tified a number of proteins whose activation allow...lls with almost 97 percent accuracy. In addition, ...nal strategy to analyze this data and specifically...its) that are active in cancer and "dormant" in no...
(Date:11/24/2009)...e/--TheBaylorCharlesA.SammonsCancerCenterhasbecome...operativegroupsintheUnitedStates.Fundedbyresearchg...ogyGroupconductsclinicaltrialstopreventandtreatcan...urvivors. ,, "Joiningthisprestigiousgroupwillal...ncerpatientsinNorthTexas,"saidAlanM.Miller,M.D.,Ph...
(Date:11/24/2009)...-USNewswire/--IPROhasachieveditsthirdconsecutiveIS...ndardfocusedonfulfillingcustomerrequirements,enhan...inessperformance.CertificationtoISO9001:2008bySGSI...yManagementSystem(QMS)haspassedarigorousexternalau...andAlbany,NewYorkaswellasatitsaffiliateLogiqual,LL...
(Date:11/24/2009)...use of inflammatory bowel disease is largely unkno... 2009 Advances in Inflammatory Bowel Diseases, the...inical & Research Conference, December 3-6 in ...mutation for Crohn’s disease. , ...9 -- The molecular cause of inflammatory bowel dis...
Breaking Medicine News(10 mins):Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2Health News:IPRO Earns Third Consecutive Quality Management Certification 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4
...cognition to encourage Americans to think, talk an..., WHITE PLAINS, N.Y., March 3 Today, the Dannon ...tivia featuring award-winning,actress and passiona...digestive health, sheds light on this,all-too-freq...
...ersal Pictures, Drama The Express Named National, ...s 2008 Light The Night ...n, who stars in the,upcoming drama The Express as ...for The Leukemia & Lymphoma Society,s,(LLS) 2008 L...
...3 The Providence Service,Corporation (Nasdaq: PR...t,financial results for its fourth quarter and yea...2008, after the market closes., Providence will h...rporate developments. Interested parties are,invit...
... CEL-SCI CORPORATION,(Amex: CVM ) provided detail... on groundbreaking activities currently underway a...and. The facility will be used,to manufacture Mult...nts. The facility, which is being built by the des...
...b Bridges Information Gap Between Clinics and ...rael, March 3 Orthocrat Ltd, a leading,provider o...ware, will,launch its unique Orthoweb on-line serv... step forward in bridging the workflow gap between...
...mmended by Annelies Boonen of Faculty of 1000 Medi...itis is diagnosed by analysing the administrative ...thors of the paper, published in Arthritis & Rheum...lf of these patients were seen in the first three ...
Other Medicine News:Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 2Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 3Health News:Actor Rob Brown Rushes to Gain Ground Against Blood Cancer 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial 2Health News:Orthocrat to Launch On-Line Service for Storing and Sharing Pre-Operative Data at AAOS 2
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--AnadysPharmaceutica...entatthe21stAnnualPiperJaffrayHealthcareConference....TheconferenceisbeingheldatTheNewYorkPalaceHotel.S...rofAnadys,willprovideanoverviewofAnadysanditsclini...orporatepresentationwillbesimultaneouslywebcastand...
(Date:11/24/2009)...ON,Calif.,Nov.24/PRNewswire-FirstCall/--ThoratecCo...dmechanicalcirculatorysupporttherapiestosave,suppo...ticipatinginthe21stAnnualPiperJaffrayHealthCareCon...cutivevicepresidentandchieffinancialofficer,willpr...ernStandardTime(5:30a.m.,PacificStandardTime). ,...
(Date:11/24/2009)...N.C.,Nov.24/PRNewswire/--PharmaceuticalInstitute,a...epharmaceuticalandbiotechindustry,todayannouncedth...Thenew HospitalMarketplace e-courseisthenewestaddi...ries,acomprehensiveseriesofe-coursesdesignedtofill...owledgeforcommercialprofessionals. ,, Thenewthr...
Breaking Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4
...ma Continues Its Success with Positive Phase IIa C...irm Potential New Application of Key,Product in AM... 9, 2007-AM-Pharma B.V., the,biopharmaceutical com...ious and inflammatory diseases, today announced th...ine Phosphatase (AP) trial,for patients with ulcer...
...ND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM),...opment and approval,of drugs for the treatment of...y announced that it will present at this,week,s C...tunities Conference in New York City. , The con... in New,York City, will run from Tuesday, July 10...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: